A detailed history of Federated Hermes, Inc. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Federated Hermes, Inc. holds 111,027 shares of BCRX stock, worth $843,805. This represents 0.0% of its overall portfolio holdings.

Number of Shares
111,027
Holding current value
$843,805
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$6.41 - $8.69 $711,683 - $964,824
111,027 New
111,027 $843,000
Q2 2022

Aug 15, 2022

SELL
$7.89 - $17.88 $2,745 - $6,222
-348 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$11.56 - $19.76 $553,643 - $946,365
-47,893 Reduced 99.28%
348 $6,000
Q4 2021

Feb 14, 2022

SELL
$11.18 - $15.46 $9.17 Million - $12.7 Million
-819,896 Reduced 94.44%
48,241 $668,000
Q3 2021

Nov 15, 2021

BUY
$14.21 - $17.65 $1.72 Million - $2.14 Million
121,166 Added 16.22%
868,137 $12.5 Million
Q2 2021

Aug 16, 2021

BUY
$9.5 - $17.24 $6.86 Million - $12.4 Million
722,057 Added 2898.2%
746,971 $11.8 Million
Q1 2021

May 13, 2021

BUY
$7.37 - $13.61 $182,407 - $336,847
24,750 Added 15091.46%
24,914 $253,000
Q4 2020

Feb 12, 2021

BUY
$3.37 - $8.61 $552 - $1,412
164 New
164 $1,000
Q4 2019

Feb 14, 2020

SELL
$1.59 - $3.45 $526,563 - $1.14 Million
-331,172 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$2.5 - $3.73 $692,860 - $1.03 Million
-277,144 Reduced 45.56%
331,172 $949,000
Q2 2019

Aug 14, 2019

SELL
$2.91 - $9.15 $497,871 - $1.57 Million
-171,090 Reduced 21.95%
608,316 $2.31 Million
Q1 2019

May 10, 2019

BUY
$7.38 - $9.72 $2.53 Million - $3.34 Million
343,269 Added 78.71%
779,406 $6.34 Million
Q4 2018

Feb 13, 2019

BUY
$6.51 - $9.6 $2.83 Million - $4.17 Million
434,756 Added 31481.25%
436,137 $3.52 Million
Q3 2018

Nov 13, 2018

BUY
$5.52 - $7.99 $7,623 - $11,034
1,381 New
1,381 $11,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.